Predictive AI for Alzheimer's Onset and Patient Management
DOI:
https://doi.org/10.5281/zenodo.20591418Keywords:
Artificial intelligence, Parkinson’s disease, predictive analytics, risk stratification, healthcare systems, formalized care guidance, early diagnosisAbstract
Aging is the most significant independent risk factor for Alzheimer’s disease (AD). Consequently, aging populations are witnessing increased AD incidence, elevating futures of cognitive decline in a growing segment of society. Predictive analytic tools are emerging to support earlier diagnosis, targeting therapeutics when they have the highest efficacy potential, and improved management, easing the care burden on both family and healthcare systems. Advances in AI/machine learning improve prediction accuracy, offering risk scores and other insights to inform practice, allocate care resources efficiently, and guide the creation of personalized treatment plans. At the same time, patient-generated health data are accumulating rapidly, enhancing screening, clinical trial recruitment, and longitudinal monitoring.
Automated Natural Language Processing (NLP) methods applied to electronic health record (EHR) data can also improve prediction prevalence and granularity. Growing EHR volume combined with augmented risk modelling enables development of predictive models for rarer conditions such as frontotemporal dementia and Alzheimer’s disease with frontal lobe involvement. Cognitive decline, dementia, or Alzheimer’s disease diagnosis within 3 years can be subjected to risk scoring. NLP can predict correspondingly non-Alzheimer’s disease dementia, vascular dementia, or frontotemporal dementia diagnosis on a similar timeframe.
References
[1] Alzheimer’s Association. (2024). 2024 Alzheimer’s disease facts and figures. Alzheimer’s & Dementia, 20(3), 1–80.
[2] Ashford, J. W. (2020). Screening for memory disorders, dementia, and Alzheimer’s disease. Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring, 12(1), e12031.
[3] Arbabshirani, M. R., Plis, S., Sui, J., & Calhoun, V. D. (2017). Single subject prediction of brain disorders in neuroimaging: Promises and pitfalls. NeuroImage, 145, 137–165.
[4] Badhwar, A., Tam, A., Dansereau, C., Orban, P., Hoffstaedter, F., & Bellec, P. (2017). Resting-state network dysfunction in Alzheimer’s disease: A systematic review and meta-analysis. Alzheimer’s & Dementia, 13(5), 536–560.
[5] Beam, A. L., & Kohane, I. S. (2018). Big data and machine learning in health care. JAMA, 319(13), 1317–1318.
[6] Bi, X. A., Wang, J., Zhang, S., & Xiao, R. (2020). Explainable AI in Alzheimer’s disease classification with neuroimaging: A review. Frontiers in Aging Neuroscience, 12, 1–17.
[7] Boccardi, M., Bocchetta, M., Morency, F. C., Collins, D. L., Nishikawa, M., Ganzola, R., & Frisoni, G. B. (2015). Training labels for hippocampal segmentation based on the EADC-ADNI harmonized protocol. Alzheimer’s & Dementia, 11(2), 175–183.
[8] Bron, E. E., Smits, M., van der Flier, W. M., Vrenken, H., Barkhof, F., Scheltens, P., Papma, J. M., & Klein, S. (2015). Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI. NeuroImage, 111, 562–579.
[9] Budd, J., Miller, B. S., Manning, E. M., Lampos, V., Zhuang, M., Edelstein, M., Rees, G., Emery, V. C., Stevens, M. M., Keegan, N., Short, M. J., Pillay, D., Manley, E., Cox, I. J., Heymann, D., Johnson, A. M., & McKendry, R. A. (2020). Digital technologies in the public-health response to COVID-19. Nature Medicine, 26(8), 1183–1192.
[10] Chen, Y., Chen, K., Zhang, X., & Li, K. (2020). Deep learning for Alzheimer’s disease: A review. IEEE Journal of Biomedical and Health Informatics, 24(9), 2417–2430.
[11] Cuocolo, R., Perillo, T., De Rosa, E., Ugga, L., & Caruso, M. (2020). Deep learning in Alzheimer’s disease: Diagnostic classification and prognostic prediction using neuroimaging. European Journal of Radiology, 130, 109118.
[12] Ding, Y., Sohn, J. H., Kawczynski, M. G., Trivedi, H., Harnish, R., Jenkins, N. W., Lituiev, D., Copeland, T. P., Aboian, M. S., & others. (2019). A deep learning model to predict a diagnosis of Alzheimer’s disease by using 18F-FDG PET of the brain. Radiology, 290(2), 456–464.
[13] Esteva, A., Robicquet, A., Ramsundar, B., Kuleshov, V., DePristo, M., Chou, K., Cui, C., Corrado, G., Thrun, S., & Dean, J. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29.
[14] Fazekas, F., Chawluk, J. B., Alavi, A., Hurtig, H. I., & Zimmerman, R. A. (1987). MR signal abnormalities at 1.5 T in Alzheimer’s dementia and normal aging. AJR American Journal of Roentgenology, 149(2), 351–356.
[15] Ferreira, D., Verhagen, C., Hernández-Cabrera, J. A., Cavallin, L., Guo, C. J., Ekman, U., ... & Westman, E. (2017). Distinct subtypes of Alzheimer’s disease based on patterns of brain atrophy: Longitudinal trajectories and clinical applications. Scientific Reports, 7, 46263.
[16] Ghassemi, M., Oakden-Rayner, L., & Beam, A. L. (2021). The false hope of current approaches to explainable artificial intelligence in health care. The Lancet Digital Health, 3(11), e745–e750.
[17] Goodfellow, I., Bengio, Y., & Courville, A. (2016). Deep learning. MIT Press.
[18] Jack, C. R., Jr., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., Liu, E., Molinuevo, J. L., Montine, T., Phelps, C., Rankin, K. P., Rowe, C. C., Scheltens, P., Siemers, E., Snyder, H. M., & Sperling, R. (2018). NIA-AA research framework: Toward a biological definition of Alzheimer’s disease. Alzheimer’s & Dementia, 14(4), 535–562.
[19] Jo, T., Nho, K., & Saykin, A. J. (2019). Deep learning in Alzheimer’s disease: Diagnostic classification and prognostic prediction using neuroimaging data. Frontiers in Aging Neuroscience, 11, 220.
[20] Johnson, K. A., Minoshima, S., Bohnen, N. I., Donohoe, K. J., Foster, N. L., Herscovitch, P., Karlawish, J. H. T., Rowe, C. C., Hedrick, S., & appropriate use criteria workgroup. (2013). Appropriate use criteria for amyloid PET: A report of the Amyloid Imaging Task Force. Alzheimer’s & Dementia, 9(1), e-1–e-16.
[21] Kamal, A., Wagner, C., & Finke, T. (2021). Machine learning in Alzheimer’s disease: A systematic review of algorithms, outcomes, and clinical impact. Journal of Alzheimer’s Disease, 83(2), 635–658.
[22] Katzman, R. (1986). Alzheimer’s disease. The New England Journal of Medicine, 314(15), 964–973.
[23] Kelley, B. J., & Petersen, R. C. (2007). Alzheimer’s disease and mild cognitive impairment. Neurologic Clinics, 25(3), 577–609.
[24] Kent, D. M., Paulus, J. K., van Klaveren, D., D’Agostino, R., Goodman, S., Hayward, R., Ioannidis, J. P. A., Patrick-Lake, B., Morton, S., Pencina, M. J., & others. (2020). The predictive approaches to treatment effect heterogeneity (PATH) statement. Annals of Internal Medicine, 172(1), 35–45.
[25] Klöppel, S., Stonnington, C. M., Chu, C., Draganski, B., Scahill, R. I., Rohrer, J. D., Fox, N. C., Jack, C. R., Jr., Ashburner, J., & Frackowiak, R. S. J. (2008). Automatic classification of MR scans in Alzheimer’s disease. Brain, 131(3), 681–689.
[26] Liu, M., Cheng, D., Yan, W., & Wang, K. (2018). Multi-modality cascaded convolutional neural networks for Alzheimer’s disease diagnosis. Neuroinformatics, 16(3–4), 295–308.
[27] Livingstone, S., & Russo, F. (2018). The GDPR, data protection, and health research. Journal of Medical Ethics, 44(4), 235–236.
[28] Lundberg, S. M., & Lee, S.-I. (2017). A unified approach to interpreting model predictions. Advances in Neural Information Processing Systems, 30, 4765–4774.
[29] Ma, D., Popuri, K., & Beg, M. F. (2020). Quantitative and interpretable evaluation of structural MRI based Alzheimer’s disease classification using deep learning. Medical Image Analysis, 64, 101730.
[30] McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Jr., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., Mohs, R. C., Morris, J. C., Rossor, M. N., Scheltens, P., Carrillo, M. C., Thies, B., & Weintraub, S. (2011). The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the NIA-AA workgroups. Alzheimer’s & Dementia, 7(3), 263–269.
[31] Morris, J. C. (1993). The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology, 43(11), 2412–2414.
[32] Petersen, R. C. (2004). Mild cognitive impairment as a diagnostic entity. Journal of Internal Medicine, 256(3), 183–194.
[33] Rajkomar, A., Dean, J., & Kohane, I. (2019). Machine learning in medicine. The New England Journal of Medicine, 380(14), 1347–1358.
[34] Reiman, E. M., Quiroz, Y. T., Fleisher, A. S., Chen, K., Velez-Pardo, C., Jimenez-Del-Rio, M., Fagan, A. M., Shah, A. R., Alvarez, S., Arbelaez, A., Giraldo, M., Acosta-Baena, N., Sperling, R. A., Dickerson, B., Stern, C. E., Tirado, V., Muñoz, C., Reiman, R. A., Huentelman, M. J., Alexander, G. E., Langbaum, J. B. S., Kosik, K. S., Tariot, P. N., & Lopera, F. (2012). Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer’s disease. The Lancet Neurology, 11(12), 1048–1056.
[35] Salloway, S., Honigberg, L. A., Cho, W., Ward, M., Friesenhahn, M., Brunstein, F., Henley, D., Chen, T., Willis, B., & others. (2022). Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in Alzheimer’s disease. JAMA Neurology, 79(1), 13–21.
[36] Scheltens, P., De Strooper, B., Kivipelto, M., Holstege, H., Chételat, G., Teunissen, C. E., Cummings, J., & van der Flier, W. M. (2021). Alzheimer’s disease. The Lancet, 397(10284), 1577–1590.
[37] Sendak, M. P., D’Arcy, J., Kashyap, S., Gao, M., Nichols, M., Corey, K., Ratliff, W., & Balu, S. (2020). A path for translation of machine learning products into healthcare delivery. EMJ Innovations, 4(1), 19–27.
[38] Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Jr., Kaye, J., Montine, T. J., Park, D. C., Reiman, E. M., Rowe, C. C., Siemers, E., Stern, Y., Yaffe, K., Carrillo, M. C., Thies, B., Morrison-Bogorad, M., Wagster, M. V., & Phelps, C. H. (2011). Toward defining the preclinical stages of Alzheimer’s disease. Alzheimer’s & Dementia, 7(3), 280–292.
[39] Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44–56.
[40] Woo, J., Kang, J., Kim, Y., & Park, H. (2017). Deep learning-based classification of Alzheimer’s disease using 3D MRI. NeuroImage: Clinical, 15, 667–676.
Additional Files
Published
Data Availability Statement
NONE
